These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 1649570)
1. Characterization of high-level quinolone resistance in Campylobacter jejuni. Gootz TD; Martin BA Antimicrob Agents Chemother; 1991 May; 35(5):840-5. PubMed ID: 1649570 [TBL] [Abstract][Full Text] [Related]
2. WQ-3810, a fluoroquinolone with difluoropyridine derivative as the R1 group exerts high potency against quinolone-resistant Koide K; Kim H; Whelan MVX; Belotindos LP; Tanomsridachchai W; Changkwanyeun R; Usui M; Ó Cróinín T; Thapa J; Nakajima C; Suzuki Y Microbiol Spectr; 2024 Oct; 12(10):e0432223. PubMed ID: 39162520 [TBL] [Abstract][Full Text] [Related]
3. Impact of mutations in DNA gyrase genes on quinolone resistance in Campylobacter jejuni. Changkwanyeun R; Yamaguchi T; Kongsoi S; Changkaew K; Yokoyama K; Kim H; Suthienkul O; Usui M; Tamura Y; Nakajima C; Suzuki Y Drug Test Anal; 2016 Oct; 8(10):1071-1076. PubMed ID: 26857529 [TBL] [Abstract][Full Text] [Related]
5. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus. Okuda J; Okamoto S; Takahata M; Nishino T Antimicrob Agents Chemother; 1991 Nov; 35(11):2288-93. PubMed ID: 1666495 [TBL] [Abstract][Full Text] [Related]
7. Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Bachoual R; Ouabdesselam S; Mory F; Lascols C; Soussy CJ; Tankovic J Microb Drug Resist; 2001; 7(3):257-61. PubMed ID: 11759087 [TBL] [Abstract][Full Text] [Related]
8. In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump. Luo N; Sahin O; Lin J; Michel LO; Zhang Q Antimicrob Agents Chemother; 2003 Jan; 47(1):390-4. PubMed ID: 12499221 [TBL] [Abstract][Full Text] [Related]
9. Resistance to quinolones in Campylobacter jejuni and Campylobacter coli from Danish broilers at farm level. Pedersen K; Wedderkopp A J Appl Microbiol; 2003; 94(1):111-9. PubMed ID: 12492931 [TBL] [Abstract][Full Text] [Related]
10. Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. Wang Y; Huang WM; Taylor DE Antimicrob Agents Chemother; 1993 Mar; 37(3):457-63. PubMed ID: 8384814 [TBL] [Abstract][Full Text] [Related]
11. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance. Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005 [TBL] [Abstract][Full Text] [Related]
12. Purification of Citrobacter freundii DNA gyrase and inhibition by quinolones. Aoyama H; Sato K; Fujii T; Fujimaki K; Inoue M; Mitsuhashi S Antimicrob Agents Chemother; 1988 Jan; 32(1):104-9. PubMed ID: 2831810 [TBL] [Abstract][Full Text] [Related]
13. Characterization of Campylobacter jejuni DNA gyrase as the target of quinolones. Changkwanyeun R; Usui M; Kongsoi S; Yokoyama K; Kim H; Suthienkul O; Changkaew K; Nakajima C; Tamura Y; Suzuki Y J Infect Chemother; 2015 Aug; 21(8):604-9. PubMed ID: 26096494 [TBL] [Abstract][Full Text] [Related]
14. Patterns of quinolone susceptibility in Campylobacter jejuni associated with different gyrA mutations. McIver C; Hogan T; White P; Tapsall J Pathology; 2004 Apr; 36(2):166-9. PubMed ID: 15203753 [TBL] [Abstract][Full Text] [Related]
15. Increased resistance to quinolones in Campylobacter jejuni: a genetic analysis of gyrA gene mutations in quinolone-resistant clinical isolates. Ruiz J; Goñi P; Marco F; Gallardo F; Mirelis B; Jimenez De Anta T; Vila J Microbiol Immunol; 1998; 42(3):223-6. PubMed ID: 9580533 [TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus. Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861 [TBL] [Abstract][Full Text] [Related]
18. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Kitamura A; Hoshino K; Kimura Y; Hayakawa I; Sato K Antimicrob Agents Chemother; 1995 Jul; 39(7):1467-71. PubMed ID: 7492087 [TBL] [Abstract][Full Text] [Related]
19. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones. Thomson KS; Sanders CC J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835 [TBL] [Abstract][Full Text] [Related]
20. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. Smith KE; Besser JM; Hedberg CW; Leano FT; Bender JB; Wicklund JH; Johnson BP; Moore KA; Osterholm MT N Engl J Med; 1999 May; 340(20):1525-32. PubMed ID: 10332013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]